Insider Selling: SiBone (NASDAQ:SIBN) Insider Sells $39,770.85 in Stock

SiBone (NASDAQ:SIBN – Get Free Report) insider Anshul Maheshwari sold 1,715 shares of the stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $23.19, for a total value of $39,770.85. Following the completion of the transaction, the insider directly owned 204,870 shares in the company, valued at $4,750,935.30. This represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anshul Maheshwari also recently made the following trade(s):

  • On Monday, November 16th, Anshul Maheshwari sold 4,665 shares of SiBone stock. The stock was sold at an average price of $23.32, for a total value of $108,787.80.
  • On Wednesday, November 4th, Anshul Maheshwari sold 3,247 shares of SiBone stock. The stock was sold at an average price of $25.00, for a total value of $81,175.00.
  • On Thursday, October 29th, Anshul Maheshwari sold 3,738 shares of SiBone stock. The shares were sold at an average price of $22.50, for a total value of $84,105.00.
  • On Monday, October 5th, Anshul Maheshwari sold 1,731 shares of SiBone stock. The shares were sold at an average price of $19.50, for a total value of $33,754.50.
  • On Friday, October 2nd, Anshul Maheshwari sold 3,318 shares of SiBone stock. The stock was sold at an average price of $18.18, for a total transaction of $60,321.24.
  • On Monday, August 24th, Anshul Maheshwari sold 11,636 shares of SiBone stock. The stock was sold at an average price of $20.11, for a total transaction of $233,999.96.
  • On Friday, August 21st, Anshul Maheshwari sold 11,228 shares of SiBone stock. The stock was sold at an average price of $20.02, for a total transaction of $224,784.56.

SiBone Stock Performance

Shares of NASDAQ SIBN opened at $23.73 on Friday. The company has a current ratio of 7.58, a quick ratio of 6.15 and a debt-to-equity ratio of 0.19. SiBone has a 12 month low of $11.48 and a 12 month high of $25.92. The company has a 50 day simple moving average of $20.88 and a two-hundred day simple moving average of $16.96. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -76.55 and a beta of 0.64.

SiBone (NASDAQ:SIBN – Get Free Report) last released its quarterly earnings data on Monday, November 2nd. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.05. The business had revenue of $55.70 million for the quarter, compared to the consensus estimate of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. As a group, analysts predict that SiBone will post -0.34 earnings per share for the current year.

Analyst Ratings Changes

SIBN has been the subject of a number of research reports. UBS Group boosted their target price on shares of SiBone from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, November 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a report on Wednesday. Wall Street Zen raised SiBone from a “hold” rating to a “buy” rating in a research report on Saturday, November 7th. Needham & Company LLC reduced their price objective on SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a research note on Tuesday, November 3rd. Finally, TD Cowen boosted their price objective on SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a report on Tuesday, November 3rd. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $25.00.

View Our Latest Research Report on SIBN

Institutional Investors Weigh In On SiBone

A number of hedge funds and other institutional investors have recently made changes to their positions in SIBN. Versant Capital Management Inc lifted its stake in shares of SiBone by 102.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company’s stock valued at $29,000 after purchasing an additional 887 shares during the period. State of Wyoming boosted its holdings in SiBone by 70.8% during the first quarter. State of Wyoming now owns 10,832 shares of the company’s stock worth $137,000 after buying an additional 4,490 shares in the last quarter. Inceptionr LLC purchased a new stake in SiBone during the first quarter worth $156,000. ADAR1 Capital Management LLC acquired a new stake in SiBone during the first quarter valued at $159,000. Finally, Pathstone Holdings LLC acquired a new stake in SiBone during the third quarter valued at $346,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

SiBone Company Profile

(Get Free Report)

SI-BONE, Inc. is a medical technology company focused on surgical solutions for conditions affecting the sacroiliac (SI) joint and related pelvic anatomy. Founded in 2008, the company develops implants and instruments used by surgeons in procedures involving the SI joint. Its products include the iFuse Implant System, a minimally invasive approach to SI joint fusion, along with related implant systems designed for SI joint and pelvic fixation procedures. SI-BONE also offers surgical instruments and training resources for healthcare professionals.

Recommended Stories

Insider Buying and Selling by Quarter for SiBone (NASDAQ:SIBN)

Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.